Key Takeaways
- •CJC-1295 and Ipamorelin stand out as growth hormone secretagogues that target different receptor pathways.
- •Growth hormone secretagogues stimulate the pituitary gland to release growth hormone by influencing the hypothalamic-pituitary axis.
- •Native GHRH (1-44) breaks down quickly due to dipeptidyl peptidase IV and other proteases, resulting in a plasma half-life under 10 minutes.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin stand out as growth hormone secretagogues that target different receptor pathways. Their combination represents the most examined GH peptide stack in existing research literature. Search volume data shows this pairing as the top growth hormone secretagogue research topic in 2026, with over 60,000 monthly global searches.
Basics of the Somatotropic Axis
Growth hormone secretagogues stimulate the pituitary gland to release growth hormone by influencing the hypothalamic-pituitary axis. The hypothalamus alternates between releasing growth hormone-releasing hormone (GHRH), which promotes GH secretion, and somatostatin, which suppresses it. GHRH reaches the anterior pituitary to activate somatotroph cells, leading to GH circulation, which then prompts the liver to generate IGF-1 for many downstream effects.
Native GHRH (1-44) breaks down quickly due to dipeptidyl peptidase IV and other proteases, resulting in a plasma half-life under 10 minutes. For more on half-lives, check the Half-Life Calculator.
CJC-1295 No DAC: Stabilized GHRH Analogue
CJC-1295 No DAC, also known as Modified GRF 1-29, is a synthetic version of GHRH featuring the first 29 active amino acids. It includes amino acid changes at positions 2, 8, 15, and 27 to prevent degradation. These alterations boost its plasma half-life to about 30 minutes while keeping full binding to the GHRH receptor.
This compound attaches to the GHRH receptor on pituitary somatotroph cells, triggering Gs protein-coupled cAMP increase. Higher cAMP levels activate protein kinase A, which modifies transcription factors like CREB to promote GH gene expression and release. Researchers favor the No DAC version for studies on pulsatile GH patterns.
The DAC version binds albumin through a lysine residue, extending half-life to 6-8 days for continuous GH rise. In contrast, No DAC mimics natural sharp pulses. Most studies pairing it with ipamorelin use the No DAC form to maintain pulsatility.
Ipamorelin: Selective GHS-R1a Agonist
Ipamorelin, a pentapeptide with sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, emerged as the first highly selective growth hormone secretagogue receptor agonist. Raun and colleagues published its discovery in 1998 after screening GHRP analogues. It differs from predecessors like GHRP-2, GHRP-6, and hexarelin by avoiding major activation of the HPA axis.
This selectivity allows strong GH stimulation without notable rises in cortisol or prolactin. Ipamorelin binds GHS-R1a, the ghrelin receptor, on somatotroph cells. It signals via Gq to raise calcium through IP3/DAG and via Gi to block adenylyl cyclase.
The calcium pathway causes quick exocytosis of stored GH granules. Explore peptide terms in the Peptide Glossary.
Synergistic Effects of the Combination
Pairing CJC-1295 with ipamorelin leverages two pathways: GHRHR from CJC-1295 and GHS-R1a from ipamorelin. These lead to GH secretion through separate signals that merge effectively. Calcium from ipamorelin and cAMP from CJC-1295 enhance protein kinase activity for greater GH granule release than expected additively.
Ipamorelin also curbs hypothalamic somatostatin release, easing inhibition on GH while CJC-1295 boosts stimulation. This results in larger, steadier GH pulses compared to single agents. Preclinical results indicate 3 to 5 times baseline GH pulses with the combo, versus 1.5 to 2 times alone.
CJC-1295 amplifies pulse height, while ipamorelin supports natural pulsatility over constant elevation. Plan cycles with the Dosage & Cycle Planner.
Key Research Data and Pharmacokinetics
Teichman et al. (2006) reported in a human study that CJC-1295 with DAC raised GH levels 2-10 times and kept IGF-1 elevated for 6 days after injection. IGF-1, mainly liver-produced from GH, drives anabolic, repair, and metabolic actions. No similar human data exists yet for No DAC or the ipamorelin combo as of 2026.
Evidence for CJC-1295 No DAC plus ipamorelin mostly comes from in vitro and animal models. These characterize mechanisms but lack extensive human trials. The stack draws interest for studies on tissue repair, body composition, and metabolism.
Research Applications and Interest
This combination appears in investigations for fat loss, healing, and metabolic models. Its dual action preserves GH pulse patterns vital for physiological effects. As of 2026, published human clinical trial data on the specific No DAC and ipamorelin pairing stays limited.
Researchers value ipamorelin's clean profile and CJC-1295's pulse mimicry. Stay updated via Latest peptide news.
In summary, CJC-1295 No DAC and ipamorelin offer complementary GH stimulation through distinct receptors and signals. Their synergy yields stronger pulses in preclinical work, fueling ongoing research interest. Future studies may clarify human applications further.
Related Research Compounds
Looking for high-purity research peptides? Browse our catalog for HPLC-verified compounds.
| Compound | Purity | Size | Price |
|---|---|---|---|
| CJC-1295 No DAC + Ipamorelin 10mg (5+5) | ≥98% | 10mg | $49.00 |
| Ipamorelin 10mg | ≥98% | 10mg | $49.00 |
| CJC-1295 DAC 5mg | ≥98% | 5mg | $49.00 |
| CJC-1295 No DAC 10mg | ≥98% | 10mg | $49.00 |